

# Usha Menon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4893672/publications.pdf>

Version: 2024-02-01

321  
papers

22,993  
citations

14655

66  
h-index

10734

138  
g-index

337  
all docs

337  
docs citations

337  
times ranked

26702  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	27.8	1,099
2	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011, 11, 719-725.	28.4	1,084
3	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	28.4	839
4	Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 945-956.	13.7	791
5	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. <i>Lancet Oncology</i> , The, 2012, 13, 385-394.	10.7	753
6	Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. <i>Genome Research</i> , 2010, 20, 440-446.	5.5	740
7	Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Lancet Oncology</i> , The, 2009, 10, 327-340.	10.7	738
8	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	6.2	711
9	Screening for ovarian cancer: a pilot randomised controlled trial. <i>Lancet</i> , The, 1999, 353, 1207-1210.	13.7	545
10	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
11	Progress and Challenges in Screening for Early Detection of Ovarian Cancer. <i>Molecular and Cellular Proteomics</i> , 2004, 3, 355-366.	3.8	375
12	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
13	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , The, 2013, 14, 853-862.	10.7	335
14	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	21.4	326
15	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. <i>Nature Genetics</i> , 2010, 42, 874-879.	21.4	321
16	Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet</i> , The, 2021, 397, 2182-2193.	13.7	313
17	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	311
18	Causal Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 135, 2373-2388.	1.6	304

#	ARTICLE	IF	CITATIONS
19	An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer. PLoS ONE, 2009, 4, e8274.	2.5	291
20	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	21.4	276
21	Contribution of Germline Mutations in the <i>RAD51B</i> , <i>RAD51C</i> , and <i>RAD51D</i> Genes to Ovarian Cancer in the Population. Journal of Clinical Oncology, 2015, 33, 2901-2907.	1.6	266
22	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
23	Dose-Response Association of CD8 <sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	7.1	260
24	Development of a Multimarker Assay for Early Detection of Ovarian Cancer. Journal of Clinical Oncology, 2010, 28, 2159-2166.	1.6	246
25	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
26	Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal Women. Journal of Clinical Oncology, 2003, 21, 206s-210.	1.6	219
27	Prospective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer. Journal of Clinical Oncology, 2005, 23, 7919-7926.	1.6	218
28	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal of the National Cancer Institute, 2014, 106, djt431-djt431.	6.3	186
29	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
30	Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncology, The, 2011, 12, 38-48.	10.7	176
31	Ovarian Cancer Prevention and Screening. Obstetrics and Gynecology, 2018, 131, 909-927.	2.4	176
32	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	3.1	169
33	Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Journal of Clinical Oncology, 2015, 33, 2062-2071.	1.6	166
34	Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection. Clinical Cancer Research, 2015, 21, 622-631.	7.0	158
35	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
36	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genetics in Medicine, 2019, 21, 2390-2400.	2.4	153

#	ARTICLE	IF	CITATIONS
37	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1411-1420.	1.6	148
38	Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, 379.	6.3	146
39	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144
40	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. <i>Journal of the National Cancer Institute</i> , 2018, 110, 714-725.	6.3	138
41	Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History-Based Testing. <i>Journal of the National Cancer Institute</i> , 2015, 107, 380.	6.3	135
42	Preanalytic Influence of Sample Handling on SELDI-TOF Serum Protein Profiles. <i>Clinical Chemistry</i> , 2007, 53, 645-656.	3.2	131
43	Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A Proof of Principle Study. <i>PLoS ONE</i> , 2008, 3, e2656.	2.5	131
44	Recruitment to multicentre trials—lessons from UKCTOCS: descriptive study. <i>BMJ: British Medical Journal</i> , 2008, 337, a2079-a2079.	2.3	128
45	Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule. <i>Journal of Clinical Oncology</i> , 2013, 31, 49-57.	1.6	126
46	The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. <i>Genome Medicine</i> , 2017, 9, 116.	8.2	122
47	Ovarian cancer screening—Current status, future directions. <i>Gynecologic Oncology</i> , 2014, 132, 490-495.	1.4	115
48	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	1.9	111
49	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i> . <i>Journal of the National Cancer Institute</i> , 2020, 112, 1242-1250.	6.3	106
50	Health Behaviors in Cancer Survivors. <i>Oncology Nursing Forum</i> , 2007, 34, 643-651.	1.2	102
51	The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. <i>Lancet Oncology</i> , The, 2013, 14, 1226-1232.	10.7	98
52	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013, 4, 1627.	12.8	98
53	Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer. <i>Journal of Proteome Research</i> , 2013, 12, 1408-1418.	3.7	96
54	Recent developments in ovarian cancer screening. <i>Current Opinion in Obstetrics and Gynecology</i> , 2000, 12, 39-42.	2.0	95

#	ARTICLE	IF	CITATIONS
55	Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). <i>European Journal of Cancer</i> , 2011, 47, 183-190.	2.8	91
56	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	12.8	90
57	Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. <i>British Journal of Cancer</i> , 2017, 116, 501-508.	6.4	86
58	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. <i>Cancer Causes and Control</i> , 2013, 24, 989-1004.	1.8	84
59	Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 671-676.	2.5	82
60	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
61	Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. <i>PLoS Medicine</i> , 2019, 16, e1002893.	8.4	78
62	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv315.	6.3	77
63	<i>ESR1/SYNE1</i> Polymorphism and Invasive Epithelial Ovarian Cancer Risk: An Ovarian Cancer Association Consortium Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 245-250.	2.5	75
64	<i>LIN28B</i> Polymorphisms Influence Susceptibility to Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 3896-3903.	0.9	75
65	Consortium analysis of 7 candidate SNPs for ovarian cancer. <i>International Journal of Cancer</i> , 2008, 123, 380-388.	5.1	73
66	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.	1.9	71
67	Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1677-1686.	2.5	70
68	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 250-261.	3.0	70
69	Screening for Ovarian Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2006, 49, 433-447.	1.1	69
70	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. <i>Clinical Cancer Research</i> , 2016, 22, 1734-1743.	7.0	69
71	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	2.9	68
72	Ovarian cancer screening: Current status and future directions. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 65, 32-45.	2.8	68

#	ARTICLE	IF	CITATIONS
73	Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 165-169.	2.3	64
74	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
75	Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. American Journal of Obstetrics and Gynecology, 2017, 217, 578.e1-578.e12.	1.3	63
76	A Randomized Trial Comparing the Effect of Two Phone-Based Interventions on Colorectal Cancer Screening Adherence. Annals of Behavioral Medicine, 2011, 42, 294-303.	2.9	60
77	Improved early detection of ovarian cancer using longitudinal multimarker models. British Journal of Cancer, 2020, 122, 847-856.	6.4	60
78	HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. International Journal of Cancer, 2009, 125, 2214-2218.	5.1	59
79	Specifying the ovarian cancer risk threshold of "premenopausal risk-reducing salpingo-oophorectomy" for ovarian cancer prevention: a cost-effectiveness analysis. Journal of Medical Genetics, 2016, 53, 591-599.	3.2	57
80	Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution. Nature Communications, 2016, 7, 11620.	12.8	56
81	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. International Journal of Cancer, 2011, 128, 2063-2074.	5.1	54
82	Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 880-890.	2.5	54
83	Rural-Urban Disparities in Time to Diagnosis and Treatment for Colorectal and Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1036-1046.	2.5	54
84	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology, 2019, 32, 1834-1846.	5.5	54
85	A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome Medicine, 2014, 6, 47.	8.2	53
86	Ovarian and cervical cancer awareness: development of two validated measurement tools. Journal of Family Planning and Reproductive Health Care, 2012, 38, 167-174.	0.8	52
87	Health Belief Model Variables as Predictors of Progression in Stage of Mammography Adoption. American Journal of Health Promotion, 2007, 21, 255-261.	1.7	51
88	Serum Peptide Profiling using MALDI Mass Spectrometry. Proteomics, 2007, 7, 77-89.	2.2	51
89	Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: Pooled analysis in five studies within the Ovarian Cancer Association Consortium. International Journal of Cancer, 2011, 128, 936-943.	5.1	49
90	Predictive Value of Symptoms for Ovarian Cancer: Comparison of Symptoms Reported by Questionnaire, Interview, and General Practitioner Notes. Journal of the National Cancer Institute, 2012, 104, 114-124.	6.3	49

#	ARTICLE	IF	CITATIONS
91	Cancer-associated autoantibodies to MUC1 and MUC4 – A blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. <i>International Journal of Cancer</i> , 2014, 134, 2180-2188.	5.1	49
92	Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF- $\kappa$ B Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. <i>EBioMedicine</i> , 2015, 2, 1331-1339.	6.1	49
93	Methylation patterns in serum DNA for early identification of disseminated breast cancer. <i>Genome Medicine</i> , 2017, 9, 115.	8.2	49
94	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019, 79, 505-517.	0.9	49
95	Evaluation of Candidate Stromal Epithelial Cross-Talk Genes Identifies Association between Risk of Serous Ovarian Cancer and TERT, a Cancer Susceptibility “Hot-Spot”. <i>PLoS Genetics</i> , 2010, 6, e1001016.	3.5	48
96	Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. <i>PLoS ONE</i> , 2011, 6, e24987.	2.5	48
97	Risk of Ovarian Cancer and the NF- $\kappa$ B Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> . <i>Cancer Research</i> , 2014, 74, 852-861.	0.9	48
98	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. <i>Clinical Cancer Research</i> , 2011, 17, 3742-3750.	7.0	47
99	Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5912-5922.	7.0	47
100	A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. <i>British Journal of Cancer</i> , 2017, 117, 666-674.	6.4	47
101	Current detection rates and time-to-detection of all identifiable <i>BRCA</i> carriers in the Greater London population. <i>Journal of Medical Genetics</i> , 2018, 55, 538-545.	3.2	45
102	Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. <i>Oncotarget</i> , 2017, 8, 3811-3825.	1.8	45
103	Heritage, health and well-being: assessing the impact of a heritage focused intervention on health and well-being. <i>International Journal of Heritage Studies</i> , 2013, 19, 229-242.	1.9	44
104	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106.	2.5	44
105	Advanced-stage cancer and time to diagnosis: An International Cancer Benchmarking Partnership (ICBP) cross-sectional study. <i>European Journal of Cancer Care</i> , 2019, 28, e13100.	1.5	44
106	Screening for ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2002, 16, 469-482.	2.8	43
107	Ovarian cancer symptom awareness and anticipated time to help-seeking for symptoms among UK women. <i>Journal of Family Planning and Reproductive Health Care</i> , 2013, 39, 163-171.	0.8	43
108	<i>PPM1D</i> Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv347.	6.3	43

#	ARTICLE	IF	CITATIONS
109	Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP). <i>BMJ Open</i> , 2018, 8, e023870.	1.9	43
110	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (ProTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	7.0	43
111	Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. <i>Oncotarget</i> , 2017, 8, 50930-50940.	1.8	43
112	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. <i>Human Molecular Genetics</i> , 2009, 18, 2297-2304.	2.9	42
113	Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. <i>Journal of Medical Genetics</i> , 2016, 53, 472-480.	3.2	42
114	Screening for ovarian cancer in the general population. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 243-256.	2.8	41
115	Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. <i>Proteomics - Clinical Applications</i> , 2014, 8, 982-993.	1.6	41
116	Protein Z: A putative novel biomarker for early detection of ovarian cancer. <i>International Journal of Cancer</i> , 2016, 138, 2984-2992.	5.1	41
117	Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. <i>Trials</i> , 2011, 12, 61.	1.6	40
118	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2015, 24, 3595-3607.	2.9	40
119	Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women. <i>Gynecologic Oncology</i> , 2015, 139, 487-494.	1.4	39
120	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. <i>Obstetrics and Gynecology</i> , 2016, 127, 828-836.	2.4	39
121	Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. <i>Clinical Cancer Research</i> , 2018, 24, 4726-4733.	7.0	39
122	Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 1555-1562.	1.7	38
123	The Effect of a Couples Intervention to Increase Breast Cancer Screening Among Korean Americans. <i>Oncology Nursing Forum</i> , 2014, 41, E185-E193.	1.2	38
124	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. <i>Journal of Medical Genetics</i> , 2018, 55, 546-554.	3.2	38
125	Evidence of a genetic link between endometriosis and ovarian cancer. <i>Fertility and Sterility</i> , 2016, 105, 35-43.e10.	1.0	37
126	Ovarian cancer screening in the general population. <i>Current Opinion in Obstetrics and Gynecology</i> , 2001, 13, 61-64.	2.0	36



#	ARTICLE	IF	CITATIONS
127	Decline in use of hormone therapy among postmenopausal women in the United Kingdom. <i>Menopause</i> , 2007, 14, 462-467.	2.0	36
128	Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. <i>Endocrine-Related Cancer</i> , 2012, 19, 137-147.	3.1	36
129	Circulating Fatty Acids and Risk of Coronary Heart Disease and Stroke: Individual Participant Data Meta-Analysis in Up to 16126 Participants. <i>Journal of the American Heart Association</i> , 2020, 9, e013131.	3.7	36
130	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , 2020, 123, 793-802.	6.4	35
131	Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000, 107, 1069-1074.	2.3	33
132	Breast and Cervical Cancer Screening Among South Asian Immigrants in the United States. <i>Cancer Nursing</i> , 2012, 35, 278-287.	1.5	33
133	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015, 21, 5264-5276.	7.0	33
134	An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation. <i>BMJ Open</i> , 2016, 6, e009641.	1.9	33
135	A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. <i>Proteomics</i> , 2010, 10, 3388-3392.	2.2	32
136	Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 431.e1-431.e12.	1.3	32
137	Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. <i>British Journal of Cancer</i> , 2019, 121, 483-489.	6.4	32
138	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32
139	Peptides Generated Ex Vivo from Serum Proteins by Tumor-Specific Exopeptidases Are Not Useful Biomarkers in Ovarian Cancer. <i>Clinical Chemistry</i> , 2010, 56, 262-271.	3.2	31
140	Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 525-530.	5.0	30
141	Circulating Methylated DNA: A New Generation of Tumor Markers: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 7205-7208.	7.0	29
142	Identifying hopelessness in population research: a validation study of two brief measures of hopelessness. <i>BMJ Open</i> , 2014, 4, e005093.	1.9	29
143	The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>British Journal of Cancer</i> , 2017, 117, 619-627.	6.4	29
144	Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the “no screen” arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Gynecologic Oncology</i> , 2020, 158, 316-322.	1.4	29

#	ARTICLE	IF	CITATIONS
145	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584.	2.5	28
146	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	5.2	28
147	Parental networks for predicting ovarian cancer. <i>Oncotarget</i> , 2018, 9, 22717-22726.	1.8	28
148	Ovarian cancer screening in the general population. <i>Ultrasound in Obstetrics and Gynecology</i> , 2000, 15, 350-353.	1.7	26
149	Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. <i>Gynecologic Oncology</i> , 2010, 119, 479-483.	1.4	26
150	Using Museum Objects to Improve Wellbeing in Mental Health Service Users and Neurological Rehabilitation Clients. <i>British Journal of Occupational Therapy</i> , 2013, 76, 208-216.	0.9	26
151	Enhanced <i>GAB2</i> Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1495-1503.	4.1	26
152	Metabolic Profiling of Adiponectin Levels in Adults. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	26
153	Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer. <i>Journal of Medical Genetics</i> , 2021, 58, 305-313.	3.2	26
154	Mixed methods evaluation of well-being benefits derived from a heritage-in-health intervention with hospital patients. <i>Arts and Health</i> , 2014, 6, 24-58.	1.6	25
155	Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy. <i>Menopause</i> , 2015, 22, 384-390.	2.0	25
156	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. <i>International Journal of Cancer</i> , 2017, 140, 2422-2435.	5.1	25
157	Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 56.e1-56.e17.	1.3	25
158	Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 286-291.	2.5	25
159	Ovarian cancer screening. <i>Cmaj</i> , 2004, 171, 323-324.	2.0	24
160	Genetic Variation in <i>TYMS</i> in the One-Carbon Transfer Pathway Is Associated with Ovarian Carcinoma Types in the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1822-1830.	2.5	24
161	The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. <i>Gynecologic Oncology</i> , 2012, 124, 185-191.	1.4	24
162	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.	2.8	24

#	ARTICLE	IF	CITATIONS
163	Interactive, Culturally Sensitive Education on Colorectal Cancer Screening. <i>Medical Care</i> , 2008, 46, S44-S50.	2.4	23
164	Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. <i>Current Opinion in Obstetrics and Gynecology</i> , 2009, 21, 31-38.	2.0	23
165	Quantitative evidence for wellbeing benefits from a heritage-in-health intervention with hospital patients. <i>International Journal of Art Therapy: Inscape</i> , 2012, 17, 63-79.	1.6	23
166	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , 2014, 133, 481-497.	3.8	23
167	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. <i>British Journal of Cancer</i> , 2017, 116, 524-535.	6.4	23
168	Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2670.	4.1	23
169	Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 34-42.	2.5	23
170	Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis. <i>Oncotarget</i> , 2018, 9, 17430-17442.	1.8	23
171	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. <i>Human Molecular Genetics</i> , 2011, 20, 2263-2272.	2.9	22
172	Ovarian Cancer Screening and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1544.	7.4	22
173	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697.	1.3	22
174	Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	22
175	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	3.0	22
176	Measuring quality and outcomes of research collaborations: An integrative review. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 261-289.	0.6	22
177	Enhancing Cancer Patient Well-Being With a Nonpharmacological, Heritage-Focused Intervention. <i>Journal of Pain and Symptom Management</i> , 2012, 44, 731-740.	1.2	21
178	Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. <i>Cancer Immunology Research</i> , 2014, 2, 332-340.	3.4	21
179	Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. <i>Cancer</i> , 2020, 126, 725-736.	4.1	21
180	Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011, 6, e20703.	2.5	21

#	ARTICLE	IF	CITATIONS
181	Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. <i>Fertility and Sterility</i> , 2011, 95, 40-45.	1.0	20
182	Investigating the therapeutic potential of a heritage-object focused intervention: a qualitative study. <i>Journal of Health Psychology</i> , 2012, 17, 809-820.	2.3	20
183	The UKCTOCS Experience—Reasons for Hope?. <i>International Journal of Gynecological Cancer</i> , 2012, 22, S18-S20.	2.5	20
184	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 987-992.	2.5	20
185	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. <i>Cancer Epidemiology</i> , 2016, 41, 71-79.	1.9	20
186	Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis. <i>Menopause</i> , 2019, 26, 1100-1009.	2.0	20
187	MicroRNA Processing and Binding Site Polymorphisms Are Not Replicated in the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1793-1797.	2.5	19
188	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	3.8	19
189	Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP). <i>BMJ Open</i> , 2019, 9, e025895.	1.9	19
190	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. <i>Cancers</i> , 2020, 12, 1241.	3.7	19
191	Polymorphism in the <i>IL18</i> Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3567-3572.	2.5	18
192	Psychological outcomes of familial ovarian cancer screening: No evidence of long-term harm. <i>Gynecologic Oncology</i> , 2012, 127, 556-563.	1.4	18
193	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
194	Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. <i>Cancers</i> , 2020, 12, 1931.	3.7	18
195	Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. <i>EBioMedicine</i> , 2022, 75, 103802.	6.1	18
196	Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. <i>Human Molecular Genetics</i> , 2009, 18, 1869-1878.	2.9	17
197	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. <i>Human Molecular Genetics</i> , 2016, 25, 3600-3612.	2.9	17
198	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. <i>Cancer Prevention Research</i> , 2019, 12, 391-400.	1.5	17

#	ARTICLE	IF	CITATIONS
199	Ovarian cancer: challenges of early detection. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 498-499.	4.3	16
200	Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 2023-2035.	3.3	16
201	Refining Ovarian Cancer Test accuracy Scores (ROckeTS): protocol for a prospective longitudinal test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer. <i>BMJ Open</i> , 2016, 6, e010333.	1.9	16
202	Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS). <i>Steroids</i> , 2016, 110, 62-69.	1.8	16
203	A quantitative performance study of two automatic methods for the diagnosis of ovarian cancer. <i>Biomedical Signal Processing and Control</i> , 2018, 46, 86-93.	5.7	16
204	The <i>Sine Qua Non</i> of Discovering Novel Biomarkers for Early Detection of Ovarian Cancer: Carefully Selected Preclinical Samples. <i>Cancer Prevention Research</i> , 2011, 4, 299-302.	1.5	15
205	Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2014, 4, e004421.	1.9	15
206	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.	1.4	15
207	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129.	6.4	15
208	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2018, 47, 450-459.	1.9	15
209	Metabolic profiles of socio-economic position: a multi-cohort analysis. <i>International Journal of Epidemiology</i> , 2021, 50, 768-782.	1.9	15
210	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. <i>Gynecologic Oncology</i> , 2020, 158, 702-709.	1.4	15
211	Screening for ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 55-62.	2.4	14
212	Conformal predictors in early diagnostics of ovarian and breast cancers. <i>Progress in Artificial Intelligence</i> , 2012, 1, 245-257.	2.4	14
213	Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 472-477.	1.7	14
214	Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK. <i>Familial Cancer</i> , 2015, 14, 521-530.	1.9	14
215	Ovarian cancer screening: UKCTOCS trial - Authors' reply. <i>Lancet, The</i> , 2016, 387, 2603-2604.	13.7	14
216	Factors Affecting Short-term Mortality in Women With Ovarian, Tubal, or Primary Peritoneal Cancer: Population-Based Cohort Analysis of English National Cancer Registration Data. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 56-65.	2.5	14

#	ARTICLE	IF	CITATIONS
217	Application of the ConNECT Framework to Precision Health and Health Disparities. <i>Nursing Research</i> , 2019, 68, 99-109.	1.7	14
218	Effects of a Community-to-Clinic Navigation Intervention on Colorectal Cancer Screening Among Underserved People. <i>Annals of Behavioral Medicine</i> , 2020, 54, 308-319.	2.9	14
219	Can Ovarian Cancer Screening Save Lives? The Question Remains Unanswered. <i>Obstetrics and Gynecology</i> , 2011, 118, 1209-1211.	2.4	13
220	Variation in NF- $\kappa$ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1421-1427.	2.5	13
221	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. <i>British Journal of Cancer</i> , 2017, 116, 1223-1228.	6.4	13
222	Change-point of multiple biomarkers in women with ovarian cancer. <i>Biomedical Signal Processing and Control</i> , 2017, 33, 169-177.	5.7	13
223	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	1.8	13
224	Novel risk models for early detection and screening of ovarian cancer. <i>Oncotarget</i> , 2017, 8, 785-797.	1.8	13
225	Withdrawal from familial ovarian cancer screening for surgery: Findings from a psychological evaluation study (PsyFOCS). <i>Gynecologic Oncology</i> , 2012, 124, 158-163.	1.4	12
226	A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants. <i>International Journal of Cancer</i> , 2019, 144, 2192-2205.	5.1	12
227	Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , 2017, 17, 603.	2.9	11
228	Ovarian cancer screening. <i>British Journal of Hospital Medicine</i> , 2002, 63, 210-213.	0.2	10
229	DNA methylation of polycomb group target genes in cores taken from breast cancer centre and periphery. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 345-355.	2.5	10
230	Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1519-1525.	2.5	10
231	Opportunistic bilateral salpingectomy (OBS) for the prevention of ovarian cancer should be offered in the context of a clinical trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 463-463.	2.3	10
232	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 780-790.	2.5	10
233	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1470-1473.	2.5	10
234	Precision health research and implementation reviewed through the conNECT framework. <i>Nursing Outlook</i> , 2019, 67, 302-310.	2.6	10

#	ARTICLE	IF	CITATIONS
235	Agreement between questionnaires and registry data on routes to diagnosis and milestone dates of the cancer diagnostic pathway. <i>Cancer Epidemiology</i> , 2020, 65, 101690.	1.9	10
236	Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , 2015, 15, 253.	2.9	9
237	Multiprobabilistic prediction in early medical diagnoses. <i>Annals of Mathematics and Artificial Intelligence</i> , 2015, 74, 203-222.	1.3	9
238	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 446-454.	2.5	9
239	Culturally Relevant Human Subjects Protection Training: A Case Study in Community-Engaged Research in the United States. <i>Journal of Immigrant and Minority Health</i> , 2018, 20, 107-114.	1.6	9
240	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561.	2.5	9
241	Surgical decision making in premenopausal <i>BRCA</i> carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study. <i>Journal of Medical Genetics</i> , 2021, , jmedgenet-2020-107501.	3.2	9
242	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	6.4	9
243	Cancer Screening Among Rural and Urban Clinics During COVID-19: A Multistate Qualitative Study. <i>JCO Oncology Practice</i> , 2022, 18, e1045-e1055.	2.9	9
244	Mathematical Models to Discriminate Between Benign and Malignant Adnexal Masses: Potential Diagnostic Improvement Using Ovarian HistoScanning. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 35-43.	2.5	8
245	Genome-Wide Association Study for Ovarian Cancer Susceptibility Using Pooled DNA. <i>Twin Research and Human Genetics</i> , 2012, 15, 615-623.	0.6	8
246	Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2014, 4, e005400-e005400.	1.9	8
247	Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>PLoS ONE</i> , 2016, 11, e0165539.	2.5	8
248	Dietary Profiles of First-Generation South Asian Indian Adolescents in the United States. <i>Journal of Immigrant and Minority Health</i> , 2017, 19, 309-317.	1.6	8
249	The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT. <i>British Journal of Cancer</i> , 2017, 116, 1111-1117.	6.4	8
250	Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2017, 7, e011822.	1.9	8
251	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. <i>American Journal of Epidemiology</i> , 2018, 187, 366-377.	3.4	8
252	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. <i>Journal of the National Cancer Institute</i> , 2021, 113, 301-308.	6.3	8

#	ARTICLE	IF	CITATIONS
253	Gene Set Analysis of Survival Following Ovarian Cancer Implicates Macrolide Binding and Intracellular Signaling Genes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 529-536.	2.5	7
254	Ovarian cancer screening has no effect on disease-specific mortality. <i>Evidence-Based Medicine</i> , 2012, 17, 47-48.	0.6	7
255	Diathermy-Induced Injury May Affect Detection of Occult Tubal Lesions at Risk-Reducing Salpingo-Oophorectomy. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 881-888.	2.5	7
256	Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 35-39.	2.3	7
257	Should Opportunistic Bilateral Salpingectomy (OBS) for Prevention of Ovarian Cancer Be Incorporated Into Routine Care or Offered in the Context of a Clinical Trial?. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 31-33.	2.5	7
258	A splicing variant of <i>TERT</i> identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. <i>International Journal of Cancer</i> , 2016, 139, 2646-2654.	5.1	7
259	The 14q32 maternally imprinted locus is a major source of longitudinally stable circulating microRNAs as measured by small RNA sequencing. <i>Scientific Reports</i> , 2019, 9, 15787.	3.3	7
260	Colorectal cancer ascertainment through cancer registries, hospital episode statistics, and self-reporting compared to confirmation by clinician: A cohort study nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Cancer Epidemiology</i> , 2019, 58, 167-174.	1.9	7
261	Approach to High Volume Enrollment in Clinical Research: Experiences from an All of Us Research Program Site. <i>Clinical and Translational Science</i> , 2020, 13, 685-692.	3.1	7
262	Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials – an ovarian cancer exemplar. <i>Trials</i> , 2021, 22, 88.	1.6	7
263	Adapting a conceptual framework to engage diverse stakeholders in genomic/precision medicine research. <i>Health Expectations</i> , 2022, , .	2.6	7
264	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , 2019, 8, 2503-2513.	2.8	6
265	The Self-Efficacy to Communicate about Sex and Intimacy (SECSI) scale: psychometric assessment in women treated for cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 1449-1457.	2.2	6
266	Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Cancers</i> , 2021, 13, 858.	3.7	6
267	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. <i>Carcinogenesis</i> , 2021, 42, 785-793.	2.8	6
268	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021, 108, 1190-1203.	6.2	6
269	Challenges of Cognitive Interviewing in Sensitive Health Topic Research. <i>Nursing Research</i> , 2021, 70, 376-382.	1.7	6
270	Adaptation of colorectal cancer screening tailored navigation content for American Indian communities and early results using the intervention. <i>Implementation Science Communications</i> , 2022, 3, 6.	2.2	6



#	ARTICLE	IF	CITATIONS
271	Ovarian cancer. <i>BMJ: British Medical Journal</i> , 2009, 339, b4650-b4650.	2.3	5
272	Psychosocial risk profiles among black male veterans administration patients non-adherent with colorectal cancer screening. <i>Psycho-Oncology</i> , 2011, 20, 1151-1160.	2.3	5
273	Adapting the coping in deliberation (CODE) framework: A multi-method approach in the context of familial ovarian cancer risk management. <i>Patient Education and Counseling</i> , 2014, 97, 200-210.	2.2	5
274	Influences on anticipated time to ovarian cancer symptom presentation in women at increased risk compared to population risk of ovarian cancer. <i>BMC Cancer</i> , 2017, 17, 814.	2.6	5
275	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	3.3	5
276	Socioeconomic Status and Ovarian Cancer Stage at Diagnosis: A Study Nested Within UKCTOCS. <i>Diagnostics</i> , 2020, 10, 89.	2.6	5
277	The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease. <i>BMC Gastroenterology</i> , 2020, 20, 104.	2.0	5
278	Multiprobabilistic Venn Predictors with Logistic Regression. <i>International Federation for Information Processing</i> , 2012, , 224-233.	0.4	5
279	Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011, 6, e19642.	2.5	5
280	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	1.8	5
281	Epithelial ovarian cancer and induction of ovulation. <i>Reviews in Gynaecological Practice</i> , 2005, 5, 131-138.	0.1	4
282	Screening of symptomatic women for ovarian cancer. <i>Lancet Oncology</i> , The, 2012, 13, e138-e139.	10.7	4
283	Randomized controlled dissemination study of community-to-clinic navigation to promote CRC screening: Study design and implications. <i>Contemporary Clinical Trials</i> , 2017, 53, 106-114.	1.8	4
284	UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. <i>Trials</i> , 2021, 22, 173.	1.6	4
285	Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP). <i>British Journal of Cancer</i> , 2022, 127, 844-854.	6.4	4
286	Screening for ovarian cancer. <i>Reviews in Gynaecological Practice</i> , 2004, 4, 156-161.	0.1	3
287	International Conference on Ovarian Cancer Screening. <i>International Journal of Gynecological Cancer</i> , 2012, 22, S1.	2.5	3
288	Preimplantation Genetic Diagnosis for Hereditary Cancers. <i>Advances in Experimental Medicine and Biology</i> , 2012, 732, 103-113.	1.6	3

#	ARTICLE	IF	CITATIONS
289	Ovarian Cancer Screening and Mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 346-348.	0.4	3
290	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424.	2.5	3
291	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	4.1	3
292	Perceptions of Cervical Cancer and Screening Behavior among Cambodian and Lao Women in the United States: An Exploratory, Mixed-Methods Study. <i>Journal of Health Care for the Poor and Underserved</i> , 2020, 31, 889-908.	0.8	3
293	Startup and implementation costs of a colorectal cancer screening tailored navigation research study. <i>Evaluation and Program Planning</i> , 2021, 85, 101907.	1.6	3
294	Feasibility and Acceptability of a Language Concordant Health Coaching Intervention Delivered by Nurses for Latinx With Type 2 Diabetes. <i>Worldviews on Evidence-Based Nursing</i> , 2021, 18, 210-216.	2.9	3
295	Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews. <i>Diagnostics</i> , 2022, 12, 1028.	2.6	3
296	OSPACS: Ultrasound image management system. <i>Source Code for Biology and Medicine</i> , 2008, 3, 11.	1.7	2
297	Gynaecological ultrasonography: expertise counts. <i>Lancet Oncology</i> , The, 2008, 9, 88-89.	10.7	2
298	Importance of serial CA125 measurements over an absolute cut-off value for the detection of asymptomatic ovarian cancer in high-risk patients. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 133, 239-240.	2.3	2
299	Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies. <i>European Journal of Epidemiology</i> , 2020, 35, 1025-1042.	5.7	2
300	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020, 10, 9688.	3.3	2
301	Communicating and Coaching in Spanish for Chronic Care. <i>Journal of Nursing Education</i> , 2021, 60, 34-37.	0.9	2
302	Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 110-118.	2.3	2
303	CA125 and Other Tumor Markers in Screening and Monitoring of Ovarian Cancer. , 2003, , 193-200.		2
304	Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>F1000Research</i> , 2018, 7, 1241.	1.6	2
305	Ovarian Cancer Screening. , 2006, , 47-68.		1
306	The value of ovarian cancer screening. <i>British Journal of Hospital Medicine (London, England)</i> : 2005), 2006, 67, 314-317.	0.5	1

#	ARTICLE	IF	CITATIONS
307	There is a need for routine peritoneal cytology at RRSO. <i>Gynecologic Oncology</i> , 2013, 128, 149-150.	1.4	1
308	Screening for gynecological cancers. <i>Expert Review of Obstetrics and Gynecology</i> , 2013, 8, 143-160.	0.4	1
309	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 338-340.	0.4	1
310	Steps towards effective gynaecological cancer screening. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 538-540.	27.6	1
311	Efficacy of a Language-Concordant Health Coaching Intervention for Latinx with Diabetes. <i>Patient Education and Counseling</i> , 2021, , .	2.2	1
312	Cost-Effectiveness of Community-to-Clinic Tailored Navigation for Colorectal Cancer Screening in an Underserved Population: Economic Evaluation Alongside a Group-Randomized Trial. <i>American Journal of Health Promotion</i> , 2022, , 089011712110684.	1.7	1
313	Sensitivity and Specificity of Multimodal and Ultrasound Screening for Ovarian Cancer, and Stage Distribution of Detected Cancers: Results of the Prevalence Screen of the United Kingdom Collaborative Trial of Ovarian Cancer Screening. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 592-593.	0.4	0
314	Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1028-1031.	2.5	0
315	Screening for Gynaecological Cancers. , 2015, , 267-281.		0
316	The double-edged sword of ovarian cancer information for women at increased risk who have previously taken part in screening. <i>Ecanermedicalscience</i> , 2016, 10, 650.	1.1	0
317	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 470-471.	0.4	0
318	Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 201-202.	1.6	0
319	Communication Among Southeast Asian Mothers and Daughters About Cervical Cancer Prevention. <i>Nursing Research</i> , 2021, 70, S73-S83.	1.7	0
320	Enhanced Liver Fibrosis Test Predicts Liver-Related Outcomes in Postmenopausal Women with Risk Factors - A Case Control Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
321	Association of adult attachment with delays in accessing specialist care in women with ovarian cancer. <i>Journal of Psychosocial Oncology</i> , 2022, 40, 491-505.	1.2	0